Oncotarget
Press Release: Continuous Treatment With Abemaciclib and Breast Cancer Cell Proliferation
Jul 6, 2022
Researchers discuss the efficacy of continuous treatment with Abemaciclib in inhibiting breast cancer cell proliferation. Abemaciclib shows higher potency than other inhibitors in inhibiting CDK4 kinase activity. It is effective regardless of HER2 status and PI3KCA gene mutation. The impact on myeloid maturation in bone marrow progenitor cells is lower compared to other inhibitors.
03:46
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Abemaciclib shows higher potency in inhibiting breast cancer cell proliferation compared to other CDK4 & 6 inhibitors.
- Continuous treatment with Abemaciclib results in sustained inhibition of breast cancer cell proliferation through apoptosis.
Deep dives
Effectiveness of AbimasaClib in Inhibiting Breast Cancer Cell Proliferation
Continuous treatment with AbimasaClib, an FDA-approved CDK IV and VI inhibitor, has shown sustained and efficient inhibition of breast cancer cell proliferation. Pharmacologically targeting cyclin-dependent kinase IV and VI has been successful, especially in patients with estrogen receptor positive breast cancer. Research indicates that AbimasaClib demonstrated higher potency in inhibiting cell proliferation in breast cancer cell lines compared to other CDK inhibitors like palbossiclib or ribosiclib. The study also highlighted AbimasaClib's impact on myeloid maturation in human bone marrow progenitor cells and its ability to induce senescence and apoptosis.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
